Lupin Launches Advanced Neuro-Rehabilitation Center Atharv Ability in Delhi
Global pharmaceutical major Lupin Limited has announced the launch of Atharv Ability, a world-class neuro-rehabilitation center located in Naraina Vihar, Delhi. The facility is dedicated to offering comprehensive, specialized, and multidisciplinary care designed for adults and children grappling with neurological disabilities.Atharv Ability aims to provide outcome-driven care that enhances mobility, improves quality of life, and supports long-term recovery for patients. The center focuses on advanced neuro-rehabilitation, integrating clinical expertise with technological precision to address critical treatment gaps. Conditions covered include stroke, traumatic brain injury, spinal cord injury, Parkinson's disease, multiple sclerosis, and pediatric neurological disorders such as cerebral palsy.
This Delhi facility expands Lupin's specialized healthcare footprint, following the successful establishment of its centers in Mumbai in 2023 and Hyderabad in 2024, aiming to increase access to high-quality neuro-rehabilitation services in the region.
Rajeev Sibal, President - India Region Formulations, commented on the inauguration, stating that rehabilitation offers a powerful opportunity to restore independence. He emphasized that the facility embodies the belief that healthcare must extend beyond mere treatment to sustained, personalized, patient-focused recovery. The expansion underscores Lupin's commitment to making high-quality neuro-rehabilitation accessible, affordable, and standardized across India.
The specialized care offered at Atharv Ability is technologically advanced. The multidisciplinary program features the use of end-effector robotics for gait and hand training, alongside AI-based balance and postural-control systems. The therapies provided are extensive, including neuro-physiotherapy, occupational, speech and swallowing, cognitive-behavioral, aqua, visual, and virtual-reality-based rehabilitation.
Lupin Limited remains a global pharmaceutical leader headquartered in Mumbai, India, with its products distributed in over 100 markets. The company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin serves multiple therapy areas globally, including respiratory, cardiovascular, central nervous system, and women's health. The organization operates 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a workforce of over 24,000 professionals.
LUPIN Stock Price Movement
Shares of Lupin Limited are edging higher to ₹2277 as of 11:16 AM today, climbing 0.83% in live trading. The stock has seen a notable intraday gain of ₹18.80, trading on robust interest with 813,391 shares processed.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.